U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623798) titled 'A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003' on May 21.
Brief Summary: The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd)
Study Start Date: June 05
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Multiple Myeloma
Intervention:
DRUG: Pomalidomide Capsules
1. The DPd treatment regimen, one cycle every 28 days: Pomalidomide 4mg/d orally, on days 1-21;
2. The PVd treatment regimen, one cycle every 21 days: Pomalidomide 4 mg/d orally, on days 1-14 of each treatment cycle;
DRUG: Bortezomib for Injection...